Antifungal Drug Development and Efficacy Evaluations

Fungal infections represent a significant global health challenge, particularly in immunocompromised populations, with annual mortality rates rivalling those of tuberculosis and HIV. Current antifungal therapy is dominated by three major classes: polyenes, azoles and echinocandins, each targeting different aspects of fungal physiology such as membrane integrity or cell‐wall synthesis. Although these agents have transformed patient care, their use is limited by dose‐dependent toxicities, drug–drug interactions and the emergence of resistance. In response, the pipeline has expanded to include long‐acting formulations, oral prodrugs and first‐in‐class molecules with novel targets. These include inhibitors of dihydroorotate dehydrogenase and Gwt1, offering alternative routes to disrupt fungal metabolism or cell‐wall assembly. Efficacy evaluations now integrate in vitro susceptibility testing (measuring minimum inhibitory concentrations), animal models of invasive infection and advanced imaging of drug distribution at sites of pathology. Clinical trials have begun to demonstrate the safety and non‐inferiority of once‐weekly echinocandins, while early human data on new agents suggest promising oral bioavailability and broad‐spectrum activity. Together, these advances underscore a multipronged strategy aimed at overcoming resistance, improving patient compliance and extending the antifungal armamentarium against priority pathogens on a global scale.

Research from Nature Portfolio

Recent studies have shown that exposure of Aspergillus fumigatus to an agricultural fungicide can select for mutations in dihydroorotate dehydrogenase that confer cross‐resistance to a novel clinical antifungal. Laboratory evolution experiments revealed non‐synonymous changes in the target enzyme without compromising fungal fitness. These findings highlight the risk of environmental fungicide use in driving resistance against emerging drugs and underscore the need for integrated stewardship across clinical and agricultural settings.

Antifungal Drug Development and Efficacy Evaluations publication trend

The graph below shows the total number of articles in antifungal drug development and efficacy evaluations across all publications each year (not limited to Nature Index journals).

Technical terms

Echinocandins: Antifungals that inhibit β‐(1,3)‐D‐glucan synthase, weakening the fungal cell wall.

Azoles: Agents that block lanosterol 14α‐demethylase, disrupting ergosterol synthesis in fungal membranes.

Polyenes: Compounds that bind ergosterol, forming pores in fungal cell membranes.

Minimum Inhibitory Concentration (MIC): The lowest drug concentration that prevents visible microbial growth in vitro.

Prodrug: An inactive precursor metabolised in vivo to release the active antifungal compound.

Dihydroorotate Dehydrogenase (DHODH): An enzyme in the pyrimidine synthesis pathway targeted by new antifungal classes.

Gwt1: A fungal enzyme required for glycosylphosphatidylinositol‐anchored protein maturation, essential for cell‐wall integrity.

Mutant Prevention Concentration: The drug concentration above which resistant mutants are unlikely to arise during therapy.

References

1. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. The Lancet Infectious Diseases (2023).
2. Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim. Nature Microbiology (2023).
3. New treatment options for critically important WHO fungal priority pathogens. Clinical Microbiology and Infection (2024).
4. Aspiring Antifungals: Review of Current Antifungal Pipeline Developments. Journal of Fungi (2020).
5. Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model. Antimicrobial Agents and Chemotherapy (2017).